Literature DB >> 32087476

Equine bone marrow-derived mesenchymal stromal cells inhibit reactive oxygen species production by neutrophils.

Gabriel Espinosa1, Anita Plaza2, Andrés Schenffeldt3, Pablo Alarcón4, Gonzalo Gajardo5, Benjamín Uberti6, Gabriel Morán7, Claudio Henríquez8.   

Abstract

BACKGROUND: Polymorphonuclear neutrophils (PMN) are the largest leukocyte population in the blood of most mammals including horses, and play an important defensive role in many infectious diseases. However, the mechanisms that increase PMN as one of the main cellular subsets in the defense against pathogens could also be involved in the pathophysiology of dysregulated inflammatory conditions. Mesenchymal stem/stromal cells (MSCs) are a heterogeneous population with a modulatory potential on the inflammatory response and are known to interact with nearly all cells of the immune system, including PMN. In this study, the in vitro modulation of equine bone marrow-derived MSCs on equine PMN phagocytosis, ROS production, and NETs generation was assessed.
RESULTS: In co-culture with MSCs, unstimulated PMN produce less ROS (2.88 % ± 1.43) than PMN in single culture (5.89 % ± 2.63) (p = 0.016). Moreover, PMN co-cultured with MSCs remain conditioned to produce fewer ROS after PMA stimulation in comparison to PMN in single culture (p < 0.05). Additionally, it was found that incubation with MSC supernatant strongly inhibited ROS production (83 % ± 6.35 less than control) without affecting phagocytosis or capacity for NETosis (p < 0.01).
CONCLUSIONS: These results suggest a modulatory effect of equine BM-derived MSCs on PMN respiratory burst, without impairing other important microbicidal functions. This supports the potential use of equine MSCs in excessive or persistent inflammatory conditions in which neutrophils are the main effector cells.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  Horse; Mesenchymal stromal cells; Neutrophils; Respiratory burst

Year:  2019        PMID: 32087476     DOI: 10.1016/j.vetimm.2019.109975

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  6 in total

Review 1.  Targeting Stem Cells in Chronic Inflammatory Diseases.

Authors:  Mari van de Vyver; Carine Smith; Yigael S L Powrie
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  The Role of MSC Therapy in Attenuating the Damaging Effects of the Cytokine Storm Induced by COVID-19 on the Heart and Cardiovascular System.

Authors:  Georgina M Ellison-Hughes; Liam Colley; Katie A O'Brien; Kirsty A Roberts; Thomas A Agbaedeng; Mark D Ross
Journal:  Front Cardiovasc Med       Date:  2020-12-09

Review 3.  Regenerative Medicine for Equine Musculoskeletal Diseases.

Authors:  Iris Ribitsch; Gil Lola Oreff; Florien Jenner
Journal:  Animals (Basel)       Date:  2021-01-19       Impact factor: 2.752

4.  Transcriptional profiling of circulating mononuclear cells from patients with chronic obstructive pulmonary disease receiving mesenchymal stromal cell infusions.

Authors:  Jesse D Armitage; Dino B A Tan; Marian Sturm; Yuben P Moodley
Journal:  Stem Cells Transl Med       Date:  2021-08-18       Impact factor: 6.940

Review 5.  Pre-conditioning Strategies for Mesenchymal Stromal/Stem Cells in Inflammatory Conditions of Livestock Species.

Authors:  Benjamin Uberti; Anita Plaza; Claudio Henríquez
Journal:  Front Vet Sci       Date:  2022-03-16

6.  Muscle Derived Mesenchymal Stem Cells Inhibit the Activity of the Free and the Neutrophil Extracellular Trap (NET)-Bond Myeloperoxidase.

Authors:  Thierry Franck; Justine Ceusters; Hélène Graide; Ange Mouithys-Mickalad; Didier Serteyn
Journal:  Cells       Date:  2021-12-10       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.